Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

GSK restructures mRNA vaccine licensing agreement in $1.54B deal GSK, J&J and Merck drop billions of dollars in M&A deals to start 2024 GSK enters into $3 billion vaccine partnership in China ...

Walmsley noted that GSK invested another $800 million in a Pennsylvania manufacturing for medicines and vaccines. “We've got 15,000 people here,” Walmsley said.

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...